CompoAtlas

SYNERPHYT® N°14 FONCTION HEPATIQUE 125ml

Food supplement declared in France, decision dated 4 March 2026

SYNERPHYT® N°14 FONCTION HEPATIQUE 125ml (SYNPHONAT) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Raphanus sativus 95 mg per day, Rosmarinus officinalis 95 mg per day, Chrysanthellum americanum 76 mg per day, Cynara scolymus 76 mg per day, Tilia platyphyllos 38 mg per day. None of the rules we check flags an issue with its declared composition.

Brand
SYNPHONAT
Food business operator placing the product on the market
Prom'innov Synphonat
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Bottle
Daily dose
4 ML
Directions for use
La dose quotidienne est de 4 mL. 2 mL 2 fois par jour pendant 15 jours puis 2,5 ml par jour le matin (demi càc) Agiter avant emploi. Laisser en bouche une minute avant ingestion. Il est conseillé de faire une cure en fin de printemps ou début d’été.
Intended populations
General population, Men and women aged 18 and over, People over 60, Men, Women
Not recommended (according to the manufacturer)
Breastfeeding women, Children (under 12), Pregnant women, Taking thyroid medication
Objectives stated by the manufacturer (these are not authorised claims)
Artères et cholestérol, Détoxifiant / Draineur, Autre : Fonction hépatique

Declaration 353975, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Raphanus sativus L.RacineExtrait fluide aqueux95 mg
Rosmarinus officinalis L.FeuilleExtrait fluide aqueux95 mg
Chrysanthellum americanum (L.) VatkeParties aériennesExtrait fluide aqueux76 mg
Cynara scolymus L.FeuilleExtrait fluide aqueux76 mg
Tilia platyphyllos Scop.EcorceExtrait fluide aqueux38 mg

Additives

E472e, E422

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

1) Déconseillé en cas d’obstruction biliaire ou d’autres troubles de la fonction biliaire, 2) Déconseillé chez la femme enceinte et allaitante, 3) L'emploi est déconseillé chez les personnes ayant une hypothyroïdie ou un traitement de la thyroïde (consulter préalablement un professionnel de santé), 4) Déconseillé en cas d'allergie croisée connue, en particulier aux plantes de la famille des Asteraceae, 5) Déconseillé aux enfants de moins de 12 ans.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Rosmarinus officinalis L.
    Read the warning, when it applies and the studies cited

    ROSEMARY – ROSMARINUS OFFICINALIS Oral

    Route of administration: Oral (ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).

    Sources cited by Health Canada (4)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Health Canada monograph dated 29 May 2026

    ROSEMARY - ROSMARINUS OFFICINALIS Topical

    Route of administration: Topical (ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).

    Sources cited by Health Canada (4)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).

    Sources cited by Health Canada (1)
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).

    Sources cited by Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 29 May 2026

  • Tilia platyphyllos Scop.
    Read the warning, when it applies and the studies cited

    Linden - TILIA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; De Smet 1993).

    Sources cited by Health Canada (2)
    • De Smet PAGM, Keller K, Hansel R, Chandler RF, editors. Adverse Effects of Herbal Drugs, Volume 2. Berlin (DE): Springer-Verlag; 1993.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : SYNPHONAT

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “SYNERPHYT® N°14 FONCTION HEPATIQUE 125ml (SYNPHONAT): composition and regulation”, https://compoatlas.com/en/supplements/products/353975-synerphyt-n-14-fonction-hepatique-125ml, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line